Clinical trials: Influenza Virus
Influenza
A Pivotal Trial to Assess the Safety and Clinical Efficacy of the M-001 as a Standalone Universal Flu Vaccine
The pivotal Phase 3 trial plans to enroll a total of approximately 12,460 participants aged 50+ over two years. Participants will be immunized twice with the M-001 universal influenza vaccine candidate or placebo and then…
- Trial name
- NCT03450915
- Testing
- M-001, Saline
- Where
- 2 sites in Poland
- Volunteers
- 12,460 people, healthy volunteers welcome
- Sponsor
- BiondVax Pharmaceuticals ltd.
Influenza Vaccines
Immunogenicity and Safety of a Cell-derived Influenza Vaccine in Elderly
A controlled, double-blind study to determine the immunogenicity and safety of influenza cell derived vaccine in elderly subjects.
- Trial name
- NCT01013675
- Testing
- Influenza Vaccine
- Where
- 12 sites in Czechia, Estonia and 1 more
- Volunteers
- 622 people, healthy volunteers welcome
- Sponsor
- Abbott Biologicals
Influenza
Safety and Efficacy Study of Fluzone® Vaccine Combined With Different Doses of JVRS-100 Adjuvant
This study is designed to assess safety, tolerability and immunogenicity of Fluzone® vaccine with four dose levels of JVRS-100 adjuvant compared to Fluzone® vaccine alone in healthy adults 18-49 years of age.
- Trial name
- H-100-001 (NCT00662272)
- Testing
- Fluzone vaccine with JVRS-100 adjuvant, Fluzone vaccine
- Where
- 2 sites in United States
- Volunteers
- 128 people, healthy volunteers welcome
- Sponsor
- Colby Pharmaceutical Company
Influenza
Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years
Today, the leading contender for the next pandemic of influenza is H5N1, a strain of avian virus. Prevention and control of a pandemic will depend on the rapid production and worldwide distribution of specific pandemic vaccines.
- Trial name
- NCT00309634
- Testing
- 4 adjuvanted pandemic influenza candidate vaccines, 4 non-adjuvanted pandemic influenza candidate vaccines
- Where
- Belgium
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Suppliers
The purpose of this study is to assess the humoral immune response and safety of the parenteral formulation of the 2010/2011-season virosomal subunit influenza vaccine Inflexal V using two different HA antigen suppliers (AdImmune…
- Trial name
- NCT01229371
- Testing
- Inflexal V influenza vaccine (CSL HA Antigen) 2010, Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011
- Where
- 2 sites in Switzerland
- Volunteers
- 440 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia
CX-4945 in Viral Community Acquired Pneumonia
This is a Phase II, multi-center, double-blind, randomized, interventional study in approximately 120 subjects to evaluate clinical benefit of CX-4945 in adult outpatients with SARS-CoV-2 and influenza viral infection-associated…
- Conditions
- Community-acquired Pneumonia, SARS-CoV-2 -Associated Pneumonia, Influenza With Pneumonia
- Trial name
- NCT06202521
- Testing
- CX-4945 (SARS-CoV-2 domain), CX-4945 (Influenza virus domain)
- Where
- 7 sites in Taiwan
- Volunteers
- 45 people
- Sponsor
- Senhwa Biosciences, Inc.
Influenza
Banlangen Granules Anti-seasonal Influenza Study
This study aimed to evaluate the efficacy and safety of the nature herbal medicine Banlangen granules in patients infected with seasonal influenza A (H1N1,H3N2) and influenza B virus.
- Trial name
- BLG (NCT02232945)
- Testing
- oseltamivir phosphate, Banlangen (Radix Isatidis) granules
- Where
- China
- Volunteers
- 177 people
- Sponsor
- Hutchison Whampoa Guangzhou Baiyunshan Chinese Medicine Company Limited
Influenza Virus
A Study to Investigate VX-787 Given to Adult Volunteers Inoculated With Live Influenza Virus
The purpose of this study is to determine the antiviral activity and safety of VX-787 given to healthy adult volunteers that have been inoculated with the influenza virus.
- Trial name
- NCT01561807
- Testing
- VX-787
- Where
- United Kingdom
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Vertex Pharmaceuticals Incorporated
Influenza
Comparison of the Safety and Immune Response of an Influenza Vaccine Made by a New Manufacturing Process With a Vaccine Made by the Traditional Manufacturing Process for Season 2003/2004
The objectives of the study are to assess the immunogenicity and safety of the inactivated influenza vaccine (whole virion, Vero cell-derived) at Day 21 and Day 180 after vaccination.
- Trial name
- NCT00161837
- Testing
- Vero Cell-derived Influenza Vaccine, Egg-derived Influenza Vaccine
- Where
- Poland
- Volunteers
- healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
Phase IV Trial to Determine the Safety and Immunogenicity of the WHO Formulation of the 2006-2007 Fluzone® Vaccine
To submit remaining available sera to Center for Biologics Evaluation and Research (CBER) for further analysis by the Food and Drug Administration (FDA), the Center for Disease Control and Prevention (CDC) and the World Health…
- Trial name
- NCT00389532
- Testing
- Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)
- Where
- United States
- Volunteers
- 116 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza A Virus
A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet Formulation
The purpose of this study is to compare the rate and extent of absorption of JNJ-63623872 following administration of a single dose as three different concept formulations with that following administration of the current…
- Trial name
- NCT02659735
- Testing
- JNJ-63623872 300 milligram (mg), JNJ-63623872 600 mg
- Where
- Belgium
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Virus Diseases, Pneumonia
Universal Anti-Viral Vaccine for Healthy Elderly Adults
This protocol tests the safety and efficacy of a novel universal vaccine concept called "allo-priming" which is designed to protect elderly adults from progression of any type of viral infection, including possible protection…
- Conditions
- Virus Diseases, Pneumonia, COVID-19 Respiratory Infection, RSV Pneumonia
- Trial name
- ALLOPRIME (NCT04441047)
- Testing
- AlloStim
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Mirror Biologics, Inc.
Influenza
A Trial to Test the Response to Different Vaccination Regimens With an H5N1 Vaccine With AS03 in Adults Aged 18-64
The purpose of the study is to characterize the immunogenicity \& safety of 2 doses of GSK's avian flu vaccine GSK 1557484A given according to different regimens to adults aged 18 to 64 years
- Trial name
- NCT00695669
- Testing
- Influenza A (H5N1) Virus Monovalent Vaccine
- Where
- 3 sites in Canada
- Volunteers
- 312 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Study to Assess the Effect of Multistrain Probiotic on the Immune Response to the Influenza Vaccination
A randomized, triple-blinded, placebo-controlled, parallel group study, to assess the effect of multistrain probiotic on the immune response to the Influenza vaccination
- Trial name
- LUPIN (NCT06103994)
- Testing
- Multistrain probiotic
- Where
- Greece
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company
Human Influenza
Safety and Immunogenicity of a Cell Derived Subunit Trivalent Nonadjuvanted Influenza Study Vaccine in Adults Aged 18 Years and Above
The present study is designed to confirm the safety and immunogenicity of cell-derived, trivalent, surface antigen, inactivated influenza vaccine in 2 age cohorts: 18 to ≤60 years and ≥61 years and the antibody response to each…
- Trial name
- NCT01880697
- Testing
- TIVc
- Where
- Germany
- Volunteers
- 126 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Influenza in Humans
A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872
This open-label, four group, fixed-sequence study will evaluate the safety and pharmacokinetic interaction of AL-794 on oseltamivir, JNJ-63623872 (formerly VX-787) and probes for P-glycoprotein, CYP3A and OATP1B1 in healthy…
- Trial name
- NCT02888327
- Testing
- AL-794, Oseltamivir, Digoxin
- Where
- United Kingdom
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Alios Biopharma Inc.
Acute Upper Respiratory Tract Infection, Influenza
Kagocel® for the Prevention of ARVI and Influenza in Adults Health Care Workers
this study evaluates the use of Kagocel for the prevention of acute respiratory viral infections (ARVI) and influenza during the epidemic rise in morbidity in Russia in the 2017-2018 season (epidemiology: number of cases during…
- Conditions
- Acute Upper Respiratory Tract Infection, Influenza, Respiratory Viral Infection
- Trial name
- NCT04611061
- Testing
- Kagocel, No one
- Where
- Russia
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Nearmedic Plus LLC
Orthomyxoviridae Infection, Influenza
Study of Inactivated, Split-Virion Influenza Vaccine Compared With Standard Fluzone Vaccine in Elderly Subjects
As a result of the safety and immunogenicity data generated from earlier dose-ranging studies, the present formulation has been selected for further development in the elderly.
- Conditions
- Orthomyxoviridae Infection, Influenza, Myxovirus Infection
- Trial name
- NCT00388583
- Testing
- Split, Inactivated, Trivalent Influenza Vaccine
- Where
- 17 sites in United States
- Volunteers
- 817 people, healthy volunteers welcome
- Sponsor
- Sanofi
Influenza, Respiratory Viral Infection
Pharmacokinetics and Bioequivalence of XC8 10 mg and 40 mg Tablets in Fasted Volunteers
Comparative study of the pharmacokinetics of XC8, film-coated tablets, 10 mg and XC8, film-coated tablets, 40 mg, when administered once in equal doses (40 mg) on an empty stomach in healthy volunteers.
- Trial name
- NCT05558462
- Testing
- XC8
- Where
- Russia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Valenta Pharm JSC
Influenza Immunisation, Healthy Volunteers
Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects
The primary objectives of the study are: To describe the safety profile of the different formulations in all participants To describe the hemagglutinin inhibition (HAI) and seroneutralization (SN) antibody responses against…
- Trial name
- FBP00004 (NCT04451954)
- Testing
- Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 1 and adjuvant, Quadrivalent RIV with H3 strain 2
- Where
- 5 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.